Terazosin And Metabolic Engagement in Alzheimer's Disease

This will be a single center, randomized, double-blind, placebo-controlled, Phase IIa study to assess the target engagement of terazosin (TZ) at up to 5 milligrams (MG) daily for patients with Alzheimer's disease. The primary goal of this study is to assess the target engagement of TZ in patients with DLB. This is a pilot study and is not powered to assess efficacy of this medication. Our hope is that this study will guide future studies of this medication for the disease modification of Alzheimer's disease. This study is also aimed to learn more about how patients with Alzheimer's disease produce and use energy and if TZ can help to reverse energy deficits that appear in Alzheimer's disease.